CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer

The study evaluated the differential gene expression in CBX5 knockdown cells compared to control shRNA expressed HCC827 cells. Briefly, human lung cancer HCC827 cells stably expressing either CBX5 shRNAs or control shRNA were analysed for gene expression. Overall design: Total RNA was extracted from all the 3 transformed cells, followed by poly-A selection and RNA-sequencing using Illumina Hi-Seq 2500 platform, with three biological replicates for each transformed sample.

本研究评估了CBX5敲低细胞相较于表达对照短发夹RNA（short hairpin RNA，shRNA）的HCC827细胞的差异基因表达情况。简言之，本研究对稳定表达CBX5 shRNA或对照shRNA的人肺癌HCC827细胞开展基因表达分析。整体实验设计：从全部3株转化细胞中提取总RNA，随后通过聚腺苷酸富集（poly-A selection）并采用Illumina HiSeq 2500平台完成RNA测序，每个转化样本设置3个生物学重复。